| Actemra IV (tocilizumab) / Roche, JW Pharma |
NCT00144612: Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Completed | 3 | 60 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Systemic Juvenile Idiopathic Arthritis | 06/05 | 06/09 | | |
NCT00144625: Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) |
|
|
| Completed | 3 | 19 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Polyarticular Juvenile Idiopathic Arthritis | 07/05 | 06/09 | | |
NCT00144534: Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP |
|
|
| Completed | 3 | 115 | Japan | MRA (Tocilizumab) | Chugai Pharmaceutical | Rheumatoid Arthritis | 08/05 | 06/09 | | |
NCT00106535 / 2004-003733-14: A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) |
|
|
| Completed | 3 | 1196 | US, Europe, RoW | tocilizumab [RoActemra/Actemra], RoActemra, Actemra, Placebo, Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 05/07 | 07/12 | | |
|
|
|
|
|
|
|
|
OPTION, NCT00106548: A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 623 | Canada, Europe, RoW | tocilizumab [RoActemra/Actemra], Placebo, Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | | 10/07 | | |
RADIATE, NCT00106522: A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy |
|
|
| Completed | 3 | 499 | US, Canada, Europe, RoW | Methotrexate, Placebo, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 11/07 | 11/07 | | |
|
|
| Completed | 3 | 1220 | US, Canada, Europe, RoW | Placebo, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/07 | 12/07 | | |
|
|
LITHE, NCT00109408: A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 673 | US, Canada, Europe, RoW | Methotrexate, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/07 | 12/07 | | |
|
|
|
|
|
NCT00144547: Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP |
|
|
| Completed | 3 | 241 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Rheumatoid Arthritis | 08/08 | 06/09 | | |
NCT00144586: Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP |
|
|
| Completed | 3 | 42 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Rheumatoid Arthritis | 08/08 | 06/09 | | |
NCT00380601: PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA) |
|
|
| Completed | 3 | 20 | Japan | MRA(Tocilizumab) | Chugai Pharmaceutical | Rheumatoid Arthritis | 08/08 | 02/09 | | |
NCT00535782 / 2007-001114-17: A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 132 | US, Canada, Europe | Tocilizumab, RoActemra, Actemra, Placebo, Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 09/08 | 01/11 | | |
|
ROSE, NCT00531817: A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 619 | US | Tocilizumab, Actemra, RoActemra, Placebo, Permitted DMARDs | Hoffmann-La Roche | Rheumatoid Arthritis | 06/09 | 03/11 | | |
|
|
| Completed | 3 | 112 | US, Canada, Europe, RoW | tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 09/09 | 08/14 | | |
|
|
|
|
|
|
|
|
NCT00754559 / 2008-000105-11: A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis. |
|
|
| Completed | 3 | 286 | Europe | Tocilizumab | Hoffmann-La Roche | Rheumatoid Arthritis | 11/09 | 11/09 | | |
NCT00848120: A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 29 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 02/10 | 02/10 | | |
NCT00810277 / 2008-004126-16: A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs |
|
|
| Completed | 3 | 14 | Europe | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 05/10 | 05/10 | | |
NCT00891020: A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) |
|
|
| Completed | 3 | 886 | US | tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice | Hoffmann-La Roche | Rheumatoid Arthritis | 07/10 | 03/11 | | |
|
|
|
|
NCT00773461: A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis. |
|
|
| Completed | 3 | 209 | RoW | tocilizumab [RoActemra/Actemra], Placebo | Hoffmann-La Roche | Rheumatoid Arthritis | 07/10 | 07/10 | | |
ACT-RAY, NCT00810199 / 2008-001847-20: A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment |
|
|
| Completed | 3 | 556 | US, Europe, RoW | tocilizumab [RoActemra/Actemra], RoActemra/Actemra, methotrexate, placebo | Hoffmann-La Roche | Rheumatoid Arthritis | 08/10 | 01/13 | | |
|
|
|
|
|
|
|
|
|
|
|
NCT01211834: Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 90 | RoW | tocilizumab, DMARDs, Placebo | JW Pharmaceutical | Rheumatoid Arthritis | 10/10 | 10/10 | | |
PICTURE, NCT01063062: A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 107 | RoW | tocilizumab [RoActemra/Actemra], Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 01/11 | 01/11 | | |
NCT01214733: A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 30 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 05/11 | 05/11 | | |
NCT00750880 / 2008-000587-17: An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. |
|
|
| Completed | 3 | 1681 | Canada, Europe, RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 07/11 | 07/11 | | |
|
|
|
|
|
|
|
| Completed | 3 | 105 | Europe | tocilizumab [RoActemra/Actemra], Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | Hoffmann-La Roche | Rheumatoid Arthritis | 07/11 | 07/11 | | |
NCT01610791: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION) |
|
|
| Completed | 3 | 121 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 08/11 | 08/11 | | |
NCT00977106 / 2008-008309-23: TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF |
|
|
| Completed | 3 | 103 | Europe | tocilizumab [RoActemra/Actemra], placebo | Hoffmann-La Roche | Rheumatoid Arthritis | 10/11 | 10/11 | | |
|
| Completed | 3 | 188 | US, Canada, Europe, RoW | Tocilizumab, RoActemra, Actemra, Placebo | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 11/11 | 01/13 | | |
|
|
|
|
|
NCT01256736: To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 89 | RoW | Tocilizumab, DMARDs | JW Pharmaceutical | Rheumatoid Arthritis | 12/11 | 11/13 | | |
|
NCT01044498: A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 46 | US | Tocilizumab, RoActemra, Actemra, Ortho-Novum® 1/35 | Hoffmann-La Roche | Rheumatoid Arthritis | 02/12 | 02/12 | | |
| Completed | 3 | 934 | Canada, Europe, RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche, Roche Products Pty Limited | Patients with severe to moderate rheumatoid arthritis | 04/12 | 04/12 | | |
NCT00996606 / 2009-012185-32: A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs |
|
|
| Completed | 3 | 58 | Europe | DMARDs, Tocilizumab, RoActemra, Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 04/12 | 04/12 | | |
| Completed | 3 | 538 | Canada, Europe, RoW | Tocilizumab, RoActemra, Actemra, Tocilizumab (MRA), TCZ | Hoffmann-La Roche | Rheumatoid Arthritis | 05/12 | 05/12 | | |
NCT01007435 / 2009-012759-12: A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 1162 | US, Canada, Europe, RoW | Tocilizumab, RoActemra, Actemra, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 05/12 | 01/14 | | |
|
|
|
NCT01353859: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs |
|
|
| Completed | 3 | 39 | RoW | tocilizumab [RoActemra/Actemra], methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 07/12 | 07/12 | | |
NCT00754572: A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 418 | RoW | tocilizumab [RoActemra/Actemra], methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 10/12 | 10/12 | | |
|
|
NCT01258712: Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients |
|
|
| Completed | 3 | 86 | RoW | Tocilizumab + methotrexate(MTX), Tocilizumab placebo + methotrexate(MTX) | Chugai Pharma Taiwan | Rheumatoid Arthritis (RA) | 10/12 | 10/12 | | |
NCT01235507: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER) |
|
|
| Completed | 3 | 71 | RoW | methotrexate, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/12 | 12/12 | | |
NCT01254331: An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment |
|
|
| Completed | 3 | 51 | RoW | tocilizumab [RoActemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 02/13 | 02/13 | | |
NCT01347983: Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients |
|
|
| Completed | 3 | 72 | RoW | Tocilizumab+Methotrexate(MTX) | Chugai Pharma Taiwan | Rheumatoid Arthritis | 03/13 | 04/13 | | |
NCT00720798 / 2005-002909-23: An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies |
|
|
| Completed | 3 | 2067 | US, Canada, Europe, RoW | Tocilizumab, RoActemra, Actemra, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids | Hoffmann-La Roche | Rheumatoid Arthritis | 04/13 | 04/13 | | |
NCT01326962: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF |
|
|
| Completed | 3 | 28 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 05/13 | 05/13 | | |
|
NCT01667471 / 2011-001097-25: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study |
|
|
| Completed | 3 | 6 | Europe | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 08/13 | 08/13 | | |
NCT01575769: An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis |
|
|
| Terminated | 3 | 41 | Europe, RoW | RoActemra/Actemra (tocilizumab) | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 12/13 | 12/13 | | |
NCT01673919: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study |
|
|
| Completed | 3 | 7 | Europe | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 01/14 | 01/14 | | |
NCT01332994 / 2010-022049-88: A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 519 | Europe | rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 02/14 | 02/14 | | |
|
|
|
NCT01587989 / 2011-001863-39: A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate |
|
|
| Completed | 3 | 77 | Europe | methotrexate, placebo, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 02/14 | 02/14 | | |
NCT01245439: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 65 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 08/14 | 08/14 | | |
NCT01034137 / 2009-013316-12: A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis |
|
|
| Completed | 3 | 317 | Europe | methotrexate, placebo MTX, placebo TCZ, tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 09/14 | 09/14 | | |
|
|
| Completed | 3 | 202 | US, Europe, RoW | sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo | Sanofi, Regeneron Pharmaceuticals | Rheumatoid Arthritis | 10/14 | 10/14 | | |
|
| Completed | 3 | 12 | Europe | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 12/14 | 12/14 | | |
NCT01665430: A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis |
|
|
| Terminated | 3 | 38 | Europe | Tocilizumab, RoActemra/Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 02/15 | 02/15 | | |
NCT01730456: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926 |
|
|
| Completed | 3 | 13 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 05/15 | 05/15 | | |
NCT01664598: An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 49 | RoW | Tocilizumab, RoActemra, Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 06/15 | 06/15 | | |
NCT01655381: A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis |
|
|
| Completed | 3 | 15 | Europe | Tocilizumab, RoActemra®, Actemra® | Hoffmann-La Roche | Rheumatoid Arthritis | 07/15 | 07/15 | | |
NCT01988012: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. |
|
|
| Completed | 3 | 100 | RoW | tocilizumab, RoActemra/Actemra | Hoffmann-La Roche | Rheumatoid Arthritis | 07/15 | 07/15 | | |
| Completed | 3 | 32 | Europe | Tocilizumab (RoActemra®), Sterile 0.9% Sodium Chloride | Hospital Clinico Universitario de Santiago, Fundación Ramón Domínguez | Thyroid Associated Ophthalmopathies, Graves´ Ophthalmopathy, Thyroid Eye Disease | 10/15 | 12/15 | | |
NCT01727986: An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study |
|
|
| Completed | 3 | 11 | RoW | tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Juvenile Idiopathic Arthritis | 11/15 | 11/15 | | |
